January 25, 2012
Bernstein Liebhard LLP is investigating whether the Board of Directors of Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ:ILMN) is breaching its fiduciary duty to its shareholders in allegedly failing to embrace a premium offer by Roche and allegedly previously resisting negotiations by Roche.
As reported, Illumina shareholders would receive $44.50 in cash for each share they own. The investigation is focused on Illumina’s actions leading up to the premium offer and the offer itself.
If you are interested in discussing your rights as an Illumina shareholder and/or have information relating to the matter, please contact U. Seth Ottensoser at (877) 779-1414 or Ottensoser@bernlieb.com.
Bernstein Liebhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last nine years.
